BUZZ—Zymeworks shares rise after Roche reaches a licensing agreement worth up to $813 millions for lung cancer drug
路透社2026/10/23 11:29October 23 - ** The pharmaceutical company Zymeworks ZYME.O saw its share price rise by 2.8% in pre-market trading, to $29.2
** The company (link) licensed its investigational lung cancer drug to Roche ROPC.S. Under this global licensing agreement, the total transaction value could reach as high as $813 million
** ZYME will receive a $55 million upfront payment, an additional $40 million, and up to $718 million in milestone payments and royalties
** Roche will obtain rights to develop and commercialize ZW209, a drug targeting DLL3—a protein commonly found on the surface of small cell lung cancer cells
** Out of 13 brokers, 5 rate the stock as “Buy” or higher, and 8 rate it as “Hold”; the median target price is $38
** As of the close of the previous trading day, the stock had increased by 8% so far this year
(To facilitate non-native English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for reader convenience. Reuters assumes no responsibility for any damages or losses caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Western Digital CFO Refutes Claims of Peaking AI Demand: No Signs of Slowdown, Cooling Off Would Actually Help Us Catch Up with Demand Gap
Western Digital's CFO strongly supports AI storage demand, stating that hyperscale cloud providers are continuously expanding capital expenditures and are already discussing supply needs for 2030 to 2031. Although the company’s quarterly results exceeded expectations and profit guidance was raised, capital expenditures more than doubled compared to the same period last year, putting pressure on free cash flow. This has raised concerns in the market about the sustainability of investment returns in AI data centers, causing the stock to close down by about 3% on Friday.
Executives reveal new monetization strategy for Meta AI: Muse is ad-free but charges for enterprise services, and takes a commission on shopping through AI agents
Meta AI chief Alexandr Wang stated that Muse is available to regular users for free and that Meta has no plans to introduce advertisements. Meta plans to offer paid services to enterprises, but specific pricing and launch timeline have not been disclosed. He also mentioned that Meta's proprietary infrastructure, security systems, and data centers provide Muse with a competitive advantage that is difficult for rivals to replicate.
Report: The Trump administration plans to remove some tariffs on Canadian goods to boost the midterm elections
According to media reports, the Trump administration plans to exempt certain Canadian agricultural and forestry products from the 50% tariff, with an announcement as early as this Friday. To maintain the overall scale of tariffs, this tax reduction may be offset by imposing additional tariffs on other Canadian goods. The move is mainly intended to help Maine Senator Susan Collins retain her seat in the midterm elections, while it could also benefit other Republican candidates in trade-dependent states.
VWO ETF Closes Flat
Crypto prices
More
